Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes

Raffaella Barone, Enrica Procaccini, Marco Chianelli, Alessio Annovazzi, Vincenzo Fiore, Mohammed Hawa, Giampaolo Nardi, Giuseppe Ronga, Paolo Pozzilli, Alberto Signore, P. Pozzilli, N. Visalli, M. G. Baroni, R. Buzzetti, L. Nisticò, E. Fioriti, C. Mesturino, L. Valente, A. Signore, M. G. CavalloG. Multari, M. A. Suppa, G. C. De Mattia, M. Cassone Faldetta, O. Laurenti, L. Lucentini, M. C. Matteoli, A. Crinò, C. Teodonio, R. Amoretti, M. Ruggeri, M. Tombesi, L. Pisano, M. G. Pennafina, C. Suraci, B. Boscherini, M. T. Fonte, M. L. Manca Bitti, S. Stoduto, G. Marietti, F. Ferrazzoli, C. Bizzarri, F. Pitocco, G. Ghirlanda

Research output: Contribution to journalArticle

Abstract

Insulin-dependent type 1 diabetes (IDDM) is caused by the autoimmune destruction of insulin-producing beta cells. Approximately 10%-20% of patients may benefit from adjuvant immunotherapy upon diagnosis of the disease in order to protect residual beta-cell function. It has been suggested that this subgroup of patients differs from others by virtue of the presence of residual pancreatic inflammation and beta-cell function. In this study we have investigated to what extent technetium-99m-labelled human polyclonal immunoglobulins (99mTc-HIG) accumulate in the pancreas of IDDM patients at the time of diagnosis and 1 year thereafter, with a view to ascertaining whether HIG scintigraphy is useful for the identification of IDDM patients with residual pancreatic inflammation. Patients with recent-onset IDDM (n = 15) were investigated at the time of diagnosis and 1 year later, and ten age- and sex-matched normal subjects were also studied. Gamma camera imaging and target to background ratio, analysed blind by three independent readers, were used to quantify the radioactivity in the pancreatic region and findings were correlated with metabolic, immunological and clinical parameters. Seven out of 15 newly diagnosed IDDM patients showed a significant accumulation of radiolabelled HIG in the pancreas (pancreas/bone ratio higher than the mean +2SD of normal subjects). One year after diagnosis, pancreatic accumulation of HIG was still detectable in most IDDM patients who were positive at the time of diagnosis. Six out of seven patients with positive scintigraphy had a partial clinical remission. These results indicate that HIG scintigraphy at the time of onset of diabetes identifies a subset of patients with residual beta-cell function who may benefit from adjuvant immunotherapy.

Original languageEnglish
Pages (from-to)503-508
Number of pages6
JournalEuropean Journal Of Nuclear Medicine
Volume25
Issue number5
DOIs
Publication statusPublished - 1998

Fingerprint

Technetium
Type 1 Diabetes Mellitus
Immunoglobulins
Radionuclide Imaging
Pancreas
Immunotherapy
Insulin
Inflammation
Insulin-Secreting Cells
Radioactivity
Bone and Bones

Keywords

  • Inflammation
  • Insulin-dependent diabetes
  • Insulitis
  • Radiolabelled immunoglobulins

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes. / Barone, Raffaella; Procaccini, Enrica; Chianelli, Marco; Annovazzi, Alessio; Fiore, Vincenzo; Hawa, Mohammed; Nardi, Giampaolo; Ronga, Giuseppe; Pozzilli, Paolo; Signore, Alberto; Pozzilli, P.; Visalli, N.; Baroni, M. G.; Buzzetti, R.; Nisticò, L.; Fioriti, E.; Mesturino, C.; Valente, L.; Signore, A.; Cavallo, M. G.; Multari, G.; Suppa, M. A.; De Mattia, G. C.; Cassone Faldetta, M.; Laurenti, O.; Lucentini, L.; Matteoli, M. C.; Crinò, A.; Teodonio, C.; Amoretti, R.; Ruggeri, M.; Tombesi, M.; Pisano, L.; Pennafina, M. G.; Suraci, C.; Boscherini, B.; Fonte, M. T.; Manca Bitti, M. L.; Stoduto, S.; Marietti, G.; Ferrazzoli, F.; Bizzarri, C.; Pitocco, F.; Ghirlanda, G.

In: European Journal Of Nuclear Medicine, Vol. 25, No. 5, 1998, p. 503-508.

Research output: Contribution to journalArticle

Barone, R, Procaccini, E, Chianelli, M, Annovazzi, A, Fiore, V, Hawa, M, Nardi, G, Ronga, G, Pozzilli, P, Signore, A, Pozzilli, P, Visalli, N, Baroni, MG, Buzzetti, R, Nisticò, L, Fioriti, E, Mesturino, C, Valente, L, Signore, A, Cavallo, MG, Multari, G, Suppa, MA, De Mattia, GC, Cassone Faldetta, M, Laurenti, O, Lucentini, L, Matteoli, MC, Crinò, A, Teodonio, C, Amoretti, R, Ruggeri, M, Tombesi, M, Pisano, L, Pennafina, MG, Suraci, C, Boscherini, B, Fonte, MT, Manca Bitti, ML, Stoduto, S, Marietti, G, Ferrazzoli, F, Bizzarri, C, Pitocco, F & Ghirlanda, G 1998, 'Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes', European Journal Of Nuclear Medicine, vol. 25, no. 5, pp. 503-508. https://doi.org/10.1007/s002590050250
Barone, Raffaella ; Procaccini, Enrica ; Chianelli, Marco ; Annovazzi, Alessio ; Fiore, Vincenzo ; Hawa, Mohammed ; Nardi, Giampaolo ; Ronga, Giuseppe ; Pozzilli, Paolo ; Signore, Alberto ; Pozzilli, P. ; Visalli, N. ; Baroni, M. G. ; Buzzetti, R. ; Nisticò, L. ; Fioriti, E. ; Mesturino, C. ; Valente, L. ; Signore, A. ; Cavallo, M. G. ; Multari, G. ; Suppa, M. A. ; De Mattia, G. C. ; Cassone Faldetta, M. ; Laurenti, O. ; Lucentini, L. ; Matteoli, M. C. ; Crinò, A. ; Teodonio, C. ; Amoretti, R. ; Ruggeri, M. ; Tombesi, M. ; Pisano, L. ; Pennafina, M. G. ; Suraci, C. ; Boscherini, B. ; Fonte, M. T. ; Manca Bitti, M. L. ; Stoduto, S. ; Marietti, G. ; Ferrazzoli, F. ; Bizzarri, C. ; Pitocco, F. ; Ghirlanda, G. / Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes. In: European Journal Of Nuclear Medicine. 1998 ; Vol. 25, No. 5. pp. 503-508.
@article{bdf12352611946a38dc831797cf852e4,
title = "Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes",
abstract = "Insulin-dependent type 1 diabetes (IDDM) is caused by the autoimmune destruction of insulin-producing beta cells. Approximately 10{\%}-20{\%} of patients may benefit from adjuvant immunotherapy upon diagnosis of the disease in order to protect residual beta-cell function. It has been suggested that this subgroup of patients differs from others by virtue of the presence of residual pancreatic inflammation and beta-cell function. In this study we have investigated to what extent technetium-99m-labelled human polyclonal immunoglobulins (99mTc-HIG) accumulate in the pancreas of IDDM patients at the time of diagnosis and 1 year thereafter, with a view to ascertaining whether HIG scintigraphy is useful for the identification of IDDM patients with residual pancreatic inflammation. Patients with recent-onset IDDM (n = 15) were investigated at the time of diagnosis and 1 year later, and ten age- and sex-matched normal subjects were also studied. Gamma camera imaging and target to background ratio, analysed blind by three independent readers, were used to quantify the radioactivity in the pancreatic region and findings were correlated with metabolic, immunological and clinical parameters. Seven out of 15 newly diagnosed IDDM patients showed a significant accumulation of radiolabelled HIG in the pancreas (pancreas/bone ratio higher than the mean +2SD of normal subjects). One year after diagnosis, pancreatic accumulation of HIG was still detectable in most IDDM patients who were positive at the time of diagnosis. Six out of seven patients with positive scintigraphy had a partial clinical remission. These results indicate that HIG scintigraphy at the time of onset of diabetes identifies a subset of patients with residual beta-cell function who may benefit from adjuvant immunotherapy.",
keywords = "Inflammation, Insulin-dependent diabetes, Insulitis, Radiolabelled immunoglobulins",
author = "Raffaella Barone and Enrica Procaccini and Marco Chianelli and Alessio Annovazzi and Vincenzo Fiore and Mohammed Hawa and Giampaolo Nardi and Giuseppe Ronga and Paolo Pozzilli and Alberto Signore and P. Pozzilli and N. Visalli and Baroni, {M. G.} and R. Buzzetti and L. Nistic{\`o} and E. Fioriti and C. Mesturino and L. Valente and A. Signore and Cavallo, {M. G.} and G. Multari and Suppa, {M. A.} and {De Mattia}, {G. C.} and {Cassone Faldetta}, M. and O. Laurenti and L. Lucentini and Matteoli, {M. C.} and A. Crin{\`o} and C. Teodonio and R. Amoretti and M. Ruggeri and M. Tombesi and L. Pisano and Pennafina, {M. G.} and C. Suraci and B. Boscherini and Fonte, {M. T.} and {Manca Bitti}, {M. L.} and S. Stoduto and G. Marietti and F. Ferrazzoli and C. Bizzarri and F. Pitocco and G. Ghirlanda",
year = "1998",
doi = "10.1007/s002590050250",
language = "English",
volume = "25",
pages = "503--508",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "5",

}

TY - JOUR

T1 - Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes

AU - Barone, Raffaella

AU - Procaccini, Enrica

AU - Chianelli, Marco

AU - Annovazzi, Alessio

AU - Fiore, Vincenzo

AU - Hawa, Mohammed

AU - Nardi, Giampaolo

AU - Ronga, Giuseppe

AU - Pozzilli, Paolo

AU - Signore, Alberto

AU - Pozzilli, P.

AU - Visalli, N.

AU - Baroni, M. G.

AU - Buzzetti, R.

AU - Nisticò, L.

AU - Fioriti, E.

AU - Mesturino, C.

AU - Valente, L.

AU - Signore, A.

AU - Cavallo, M. G.

AU - Multari, G.

AU - Suppa, M. A.

AU - De Mattia, G. C.

AU - Cassone Faldetta, M.

AU - Laurenti, O.

AU - Lucentini, L.

AU - Matteoli, M. C.

AU - Crinò, A.

AU - Teodonio, C.

AU - Amoretti, R.

AU - Ruggeri, M.

AU - Tombesi, M.

AU - Pisano, L.

AU - Pennafina, M. G.

AU - Suraci, C.

AU - Boscherini, B.

AU - Fonte, M. T.

AU - Manca Bitti, M. L.

AU - Stoduto, S.

AU - Marietti, G.

AU - Ferrazzoli, F.

AU - Bizzarri, C.

AU - Pitocco, F.

AU - Ghirlanda, G.

PY - 1998

Y1 - 1998

N2 - Insulin-dependent type 1 diabetes (IDDM) is caused by the autoimmune destruction of insulin-producing beta cells. Approximately 10%-20% of patients may benefit from adjuvant immunotherapy upon diagnosis of the disease in order to protect residual beta-cell function. It has been suggested that this subgroup of patients differs from others by virtue of the presence of residual pancreatic inflammation and beta-cell function. In this study we have investigated to what extent technetium-99m-labelled human polyclonal immunoglobulins (99mTc-HIG) accumulate in the pancreas of IDDM patients at the time of diagnosis and 1 year thereafter, with a view to ascertaining whether HIG scintigraphy is useful for the identification of IDDM patients with residual pancreatic inflammation. Patients with recent-onset IDDM (n = 15) were investigated at the time of diagnosis and 1 year later, and ten age- and sex-matched normal subjects were also studied. Gamma camera imaging and target to background ratio, analysed blind by three independent readers, were used to quantify the radioactivity in the pancreatic region and findings were correlated with metabolic, immunological and clinical parameters. Seven out of 15 newly diagnosed IDDM patients showed a significant accumulation of radiolabelled HIG in the pancreas (pancreas/bone ratio higher than the mean +2SD of normal subjects). One year after diagnosis, pancreatic accumulation of HIG was still detectable in most IDDM patients who were positive at the time of diagnosis. Six out of seven patients with positive scintigraphy had a partial clinical remission. These results indicate that HIG scintigraphy at the time of onset of diabetes identifies a subset of patients with residual beta-cell function who may benefit from adjuvant immunotherapy.

AB - Insulin-dependent type 1 diabetes (IDDM) is caused by the autoimmune destruction of insulin-producing beta cells. Approximately 10%-20% of patients may benefit from adjuvant immunotherapy upon diagnosis of the disease in order to protect residual beta-cell function. It has been suggested that this subgroup of patients differs from others by virtue of the presence of residual pancreatic inflammation and beta-cell function. In this study we have investigated to what extent technetium-99m-labelled human polyclonal immunoglobulins (99mTc-HIG) accumulate in the pancreas of IDDM patients at the time of diagnosis and 1 year thereafter, with a view to ascertaining whether HIG scintigraphy is useful for the identification of IDDM patients with residual pancreatic inflammation. Patients with recent-onset IDDM (n = 15) were investigated at the time of diagnosis and 1 year later, and ten age- and sex-matched normal subjects were also studied. Gamma camera imaging and target to background ratio, analysed blind by three independent readers, were used to quantify the radioactivity in the pancreatic region and findings were correlated with metabolic, immunological and clinical parameters. Seven out of 15 newly diagnosed IDDM patients showed a significant accumulation of radiolabelled HIG in the pancreas (pancreas/bone ratio higher than the mean +2SD of normal subjects). One year after diagnosis, pancreatic accumulation of HIG was still detectable in most IDDM patients who were positive at the time of diagnosis. Six out of seven patients with positive scintigraphy had a partial clinical remission. These results indicate that HIG scintigraphy at the time of onset of diabetes identifies a subset of patients with residual beta-cell function who may benefit from adjuvant immunotherapy.

KW - Inflammation

KW - Insulin-dependent diabetes

KW - Insulitis

KW - Radiolabelled immunoglobulins

UR - http://www.scopus.com/inward/record.url?scp=15644365900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644365900&partnerID=8YFLogxK

U2 - 10.1007/s002590050250

DO - 10.1007/s002590050250

M3 - Article

C2 - 9575246

AN - SCOPUS:15644365900

VL - 25

SP - 503

EP - 508

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 5

ER -